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ABSTRACT
Pyrazole is a five-membered heterocyclic compound containing two nitrogen atoms. Due to its biological significance, design of novel pyrazole 
derivatives has become an interesting research area. We report the current progress in the development of anticancer agents containing pyrazole 
ring covering the time span of the past few years (2013–2016). The presence of this nucleus is accompanied with some side chains, functional groups, 
or in combination with other nucleus such as thiazole, thiourea, glucosamine, naphthalimide, and benzofuran. Several biologically active pyrazoles 
synthesized by numerous researchers across the world are summarized in this paper.
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INTRODUCTION
N-containing heterocycles are molecules which have unique structural 
motif and found extensively in natural products such as hormones, 
alkaloids, and vitamins [1,2]. Pyrazole represents one of the most 
prominent classes of heterocycles exhibiting large spectrum of biological 
performances such as anticancer [3,4], antitumor [5], anti-AIDS [6], 
antimicrobial [7,8], antimalarial [9], and antitubercular [10]. It gained 
great attention since the privileged structure is commonly found as active 
constituent in commercial drugs (Fig. 1), such as lonazolac 1 nonsteroidal 
anti-inflammatory drug (NSAID), pyrazofurin 2 (anticancer), 
difenamizole 3 (analgesic), and deracoxib 4 (NSAID) [11-14]. The 
simplicity of preparation and rich of biological benefits of pyrazole and 
its derivatives make them as interesting platform chemicals for organic, 
medicinal, and pharmaceutical chemistry.
Chemically, in the basic structure, pyrazole has two nitrogen atoms at 
adjacent position in the five-membered ring [15]. Molecular formula of 
pyrazole is C3H4N2 which has 6 π electrons delocalized in ring forms an 
aromatic system. Pyrazole is closely linked with several of its reduced 
or oxidized form such as pyrazoline, pyrazolidine, and pyrazolone 
(Fig. 2). Unlike pyrazole, pyrazoline, and pyrazolidine are not aromatic 
compounds due to lack of conjugation and delocalization of π electrons. 
The main skeletal of pyrazole and its related structures can be utilized 
as important building blocks in organic synthetic for the design of 
a variety of biologically active compounds [16,17]. In this review, we 
collect research result about the potency of pyrazole derivatives as 
anticancer agents.
DISCUSSION
With the shift in the people’s living habit, cancer has become a 
deadly disease in both developed and developing countries across 
the globe [18]. It is caused by miss-regulation or mutation of the cell 
cycle that regulate genes and proteins. Cancer is a group of various 
diseases, i.e., lung cancer, cervical cancer, prostate cancer, and breast 
cancer, and all of them are characterized by an abnormal control of 
cell growth [19]. Despite many clinically successful anticancer drugs 
have been developed either natural products or synthetic derivatives 
of naturally occurring lead compounds, there are still limitations in the 
treatment of cancer including the effectiveness of drugs and serious 
side effects [20]. Hence, many pyrazole-based compounds have been 
synthesized and screened by scientists. 
Discovery of some pyrazoles in the year 2013
Molecular structures of pyrazole derivatives prepared by several 
research group during 2013 were presented in Fig. 3. Some new 
compounds of pyrazole-based 1,3-thiazoles and 1,3,4-thiadiazoles 
were synthesized by Dawood et al. and evaluated for anticancer activity 
against HepG2, MCF-7, and A549 cell lines [21]. Following in vitro 
evaluation, it was reported that there are 9 compounds (9a-c, 10a-b, 11, 
and 12a-c) that have IC50 values below 100 µM. Compound 9a showed 
anticancer potency with IC50 value of 67.11 µM against HepG2 cell line 
but inactive against MCF-7 and A549 cell lines. Introduction of electron 
donating group (4-Me and 4-OMe) to compounds 9b and 9c enhanced 
their anticancer activity with IC50 range of 20.74-64.50 µM against the 
aforementioned cancer cell lines. Compounds 10a and 10b (IC50 values 
between 8-16 µM) were reported as the most active compounds of the 
series against three model cancer cell lines. They have greater activity 
compared to compounds 11 and 12a-c [21]. A new series of pyrazole-
based acyl thiourea derivatives synthesized by Koca et al. was screened 
for their anticancer potential against DLD-1, HepG2, and Jurkat cell 
lines [22]. Compounds 13a-k have shown good anticancer activity 
which has % cell viability after 48 h in the range of 6.00-90.00 (against 
Jurkat cell line), 40.25-96.56 (against DLD-1 cell line), and 20.81-51.24 
(against HepG2 cell line). Compound 13a is the most potent pyrazole in 
this series which has 6.00 ± 0.61% cell viability against Jurkat cell line 
at sample concentration of 10−4 M [22].
El-Gamal et al. developed novel structures bearing triarylpyrazole 
scaffold and determined their anticancer performance [23]. Surprisingly, 
all tested compounds (14a-m) demonstrated superior anticancer 
activity against over 60 cancer cell lines including RPMI-8226, HOP-92, 
KM12, SF-295, MDA-MB-435, OVCAR-3, A498, PC-3, and MDA-MB-468. 
Triarylpyrazole 14h was reported as the most active anticancer agent 
with IC50 ≤0.63 µM [23]. Another series of pyrazole derivatives in the 
form of 2-oxo-2H-chromenylpyrazolecarboxylates 15a-c and 16a-d with 
a potent performance against prostate (DU-145), lung adenocarcinoma 
(A549), and cervical (HeLa) cancer cell lines was described by Kumar 
et al. [24]. These compounds displayed appreciable anticancer potency 
against all the tested cell lines with IC50 values between 24 and 40 µM 
(on DU-149), 18-52 µM (on A549), and 22-50 µM (on HeLa).
Thirty derivatives of pyrazole and pyrazoline bearing isosteviol 
moiety (17a-17ad) were synthesized by Zhu et al. [25]. The cytotoxic 
activities were evaluated in vitro against four human cancer cell 
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Fig. 1: Several commercial drugs containing pyrazole ring
Fig. 2: Basic structure of pyrazole and related compounds
lines. Out of the synthesized compounds, compound 17t was found 
to be the most potent anticancer candidate with IC50 values of 1.09, 
2.71, 3.18, and 13.52 µM against Raji, SGC7901, A549, and HeLa, 
respectively [25].
Discovery of some pyrazoles in the year 2014
Fig. 4 showed new pyrazoles synthesized in 2014. Grosse et al. 
presented a paper on imidazo[1,2-b]pyrazoles that are useful as 
inhibitors of 5 human and 1 murine cancer cell lines [26]. Of the 39 
compounds screened in vitro by MTT assay, compound 18a, 18b, 19, and 
20 displayed an IC50 below 10 µM. The structure-activity relationship 
analysis resulted preliminary conclusion that C-7 aminomethylated 
compounds containing 6-membered cycle like N-methylpiperazine or 
morpholine have high anticancer potency. On the contrary, in C-2/C-
3/C-6/C-7 tetrasubstituted imidazo[1,2-b]pyrazoles, the presence of a 
fourth substituent has not influence to enhance the anticancer activity, 
except in the case of compound 20 [26].
The synthesis and inhibitory activity against A549 lung cancer cell line 
of a series of 2-(3,5-dimethyl-1H-pyrazol-1-yl)-1-arylethanones were 
described by Kumar et al. [27]. In vitro anticancer test was performed 
against colon (HCT-116 and HT-29), lung (A549), prostate (DU-145), 
and ovarian (SKOV3) cell lines. Compound 21a was found to be cytotoxic 
to all cancer cell lines, except SKOV3. Furthermore, compound 21a and 
21b exhibited similar activity as carboplatin in inhibiting viability of 
A549 cancer cell line [27]. Li et al. reported the synthesis of 4-pyrazolyl-
1,8-naphthalimide derivatives (22a-l) [28]. All compounds were toxic 
against MCF-7 and HeLa that have IC50 values of 0.51-17.01 µM (on 
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molecules, compound 23 with 2-chloro-4-pyridinyl group in the amide 
part showed promising cytotoxic performance against all the above-
mentioned cancer cell lines with IC50 values of 1.6 µM (on liver cancer 
cell), 3.3 µM (on breast cancer cell), and 1.1 µM (on colon carcinoma 
cancer cell). It induced apoptosis with significant cell cycle arrest at 
SubG1/G1 phase in human liver cancer cell line.
A series of derivative compounds which contain pyrazole-thiazole-
naphthalene hybrid was synthesized by Yuan et al. [30]. Of the 28 
compounds evaluated, 30d exhibited the most potent inhibitory 
activity against HeLa with IC50 of 0.86 µM. SAR analysis revealed that 
the presence of electron donating group enhanced the antiproliferative 
activity (-OMe > -Me > -H > -Br > -Cl > -F). Moreover, compound with 
4-thiazolinone moiety displayed higher inhibitory activity than 
compound bearing a 4-phenylthiazolinone group.
Discovery of some pyrazoles in the year 2015
El-Karim et al. discovered a novel series of benzofuran-pyrazole 
derivatives as anticancer agents [31]. Resultantly, compound 31a 
exhibited a notable anticancer activity against Leukemia CCRF-CEM, 
MOLT-4, ovarian cancer IGROV1, CNS cancer SNB-75, melanoma 
SK-MEL-2, colon cancer HCC-2998, renal cancer 786-0, RXF 393, lung 
cancer HOP-92, breast cancer HS 578T, and T-47D lines with IC50 values 
between 1.00 and 2.71 µM. Molecular docking study revealed that 
compound 31a has fulfilled Lipinskiís rule of five. Furthermore, good 
anticancer activity of compound 31a, 31b, and 32 could be attributed 
to the presence of benzofuran-N-phenylpyrazole skeleton together 
with the 3-pyrrolo/furano-N-acetyl pyrazoline or 3-pyrrolo-isoxazole 
ring systems. Kamal et al. developed a series of pyrazole-oxindole 
conjugates through Knoevenagel condensation [32]. Compound 33a-c 
was proved to be the three best molecules in inhibiting the cell growth 
of HeLa, A549, MCF-7, and DU-145 with IC50 values in the range of 
2.4–9.3 µM. The presence of a single chloro or methoxy group at D ring 
was found to be important for the antiproliferative and antitubulin 
polymerization activity. Notably, from Zebrafish screening assays 
showed that compound 33a and 33c caused developmental defect of 
embryos (Fig. 5).
Among the 1,3-diphenyl-1H-pyrazoles that contain benzimidazole 
moiety developed by Reddy et al., most of the synthesized compounds 
significantly inhibit the proliferation of cancer cell and some of 
them have excellent antiproliferative action than 5-fluorouracil as 
control [33]. Compound 34a-c demonstrated potent large spectrum 
cytotoxicity against A549, HeLa, and MCF-7 cancer cell lines with 
IC50 values in the range of 0.83–1.81 µM. Compound 35 which has 
5-fluoro-pyridin and 4-fluoro-phenyl moiety showed the highest 
inhibition in human MCF-7 and HeLa cell lines among the new 
series of biomolecules synthesized by Sankappa et al. [34]. A new 
series of steroidal oxadiazole, pyrrole, and pyrazole derivatives was 
developed by Shamsuzzaman et al. resulted in compound 36 as the 
most promising anticancer candidate [4]. This study also reported 
that pyrazole moiety after being attached with steroidal skeleton 
may be the factor responsible for enhanced anticancer properties 
of pyrazoles. Various novel pyrazole-5-carboxamide and pyrazole-
pyrimidine derivatives were synthesized by Shi et al. and were 
tested for antiproliferative activity against MGC-803, SGC-7901, and 
Bcap-37 cell lines in vitro [35]. Compound 37 was recorded to be a 
promising anticancer agent. Several coumarin substituted thiazolyl-
3-aryl-pyrazole-4-carbaldehydes were designed by Vaarla et al. [36]. 
Compound 38a and 38b showed an appreciated inhibition against 
MCF-7, HeLa, and DU-145 cell lines.
Discovery of some pyrazoles in the year 2016
Two series of substituted phenyl pyrazoles were developed by Alam 
et al. and were tested as inhibitor for several cancer cell lines [3]. As 
a result, compound 39 displayed superior cytotoxicity with an IC50 
value of 14.31 ± 0.90 µM for MCF-7, 8.55 ± 0.35 µM for NCI-H460, 
and 7.01 ± 0.60 µM for HeLa. This compound showed in silico 
Fig. 3: Pyrazole derivatives discovered during the year 2013
MCF-7) and 3.09-16.60 µM (on HeLa). Toward these cells, compound 
22b, 22h, and 22i have higher cytotoxicity than amonafide (control). On 
A549 cell, most of the synthesized compounds have good anticancer 
activity (IC50 values between 5.09 and 25.36 µM), except compound 22d 
and 22l, displayed IC50 values more than 50 µM [28].
The compounds of 5-(p-tolyl)-1-(quinoline-2-yl)pyrazole-3-carboxylic 
acid amides with potent antiproliferative activity against human 
liver, breast, and colon carcinoma cancer cell lines were developed 
by Pirol et al. [29]. In the series that contain 15 synthesized bioactive 
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Fig. 4: Pyrazole derivatives discovered during the year 2014
drug-likeliness properties within the acceptable range. Dai et al. 
synthesized a series of novel pyrazole oxime derivatives containing 
a 1,2,3-thiadiazole scaffold [37]. Compounds 40a, 40c-e were the 
most active against HCT-116 cells with IC50 values below 8.50 µM. 
It was better than 5-fluorouracil. In addition, compounds 40b, 40d, 
and 40e presented good inhibitory performance against SGC-7901 
with the IC50 between 8.64 and 11.46 µM, which were better than 
5-fluorouracil (Fig. 6).
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Fig. 5: Pyrazole derivatives discovered during the year 2015
Hafez et al. investigated the synthesis of novel pyrazole derivatives 
decorated with oxa/thiadiazolyl, pyrazolyl moieties, and pyrazolo[4,3-d]
pyrimidines as potential anticancer agents [38]. Among the designed 
compounds, compounds 41a, 41b, and 42 indicated higher anticancer 
activity than doxorubicin as standard drug. A novel series of 6-aryl-
3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-ones were 
prepared by Rahmouni et al. in a single step through the reaction of 
carboxamide with several aromatic aldehydes in the presence of 
iodine [39]. From the results, it was monitored that compound 43 had 
the highest cytotoxicity against HCT-116 and MCF-7 cancer cell lines 
at 100 µM with % inhibition values of 75.4 ± 8.9 and 72.0 ± 4.9%, 
respectively. To the various products evaluated, the HCT-116 colon cell 
line is more sensitive than MCF-7 breast cancer cell line. In another 
research, the development of a small library of 1-acetyl-5-aryl-4,5-
dihydro-1H-pyrazoles (44a-g) was described by Ratković et al. [40]. 
Further, it was noted that compounds 44c, 44d, and 44g were the most 
selective inhibitor of HCT-116 cell line. 30 compounds in the series of 
(Z)-1-(1,3-diphenyl-1H-pyrazol-4-yl)-3-(phenylamino)prop-2-en-1-
ones were synthesized by Reddy et al. and were investigated against 
HT-29, PC-3, A-549, U87MG, and HaCaT cancer cell lines [41]. The 
compounds 45a-c exhibited an excellent and broad spectrum of growth 
inhibition on all the tested cancer cells with IC50 values in the range of 
1.25-3.98 µM. A novel series of selective inhibitor for HGC-27, PC-3, EC-
109, and MCF-7 was developed by Wang et al. [42]. Indolyl substituted 
1,4,6,7-tetrahydropyrano[4,3-c]pyrazoles were synthesized, and from 
bioactivity studies, it was found that compounds 46a and 46b were the 
most selective to inhibit MCF-7 cell line with activity close to that of 
doxorubicin. Compound 46c selectively inhibited the growth of HGC-27 
and PC-3 cell lines, whereas compound 46d was the most potent for the 
EC-109 inhibitor.
CONCLUSION AND FUTURE PROSPECT
The main goal of this review is focused on pyrazole heterocyclic ring 
decorated with various functional groups. These compounds displayed 
a large spectrum of biological performance, especially as anticancer 
agents. Some of them were selective for certain cancer cell line with 
activity greater than reference drugs. The design and development of 
anticancer agents become an interesting field of research since cancer 
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Fig. 6: Pyrazole derivatives discovered during the year 2016 
is the deadly disease in the world. In future, we hope researchers 
will explore new candidates for anticancer through the green organic 
synthesis of functional molecules.
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